Zobrazeno 1 - 10
of 355
pro vyhledávání: '"Thomas P Monath"'
Autor:
Eleonora Vianello, PhD, Patricia Gonzalez-Dias, MSc, Suzanne van Veen, BSc, Carmen G Engele, BSc, Edwin Quinten, BSc, Thomas P Monath, MD, Donata Medaglini, ProfPhD, Francesco Santoro, PhD, Angela Huttner, MD, Sheri Dubey, PhD, Michael Eichberg, PhD, Francis M Ndungu, PhD, Peter G Kremsner, ProfMD, Paulin N Essone, PhD, Selidji Todagbe Agnandji, MD, Claire-Anne Siegrist, ProfMD, Helder I Nakaya, PhD, Tom H M Ottenhoff, ProfMD, Mariëlle C Haks, PhD, Selidij T Agnandij, Rafi Ahmed, Jenna Anderson, Floriane Auderset, Philip Bejon, Luisa Borgianni, Jessica Brosnahan, Annalisa Ciabattini, Olivier Engler, Mariëlle C Haks, Ali M Harandi, Donald G Heppner, Alice Gerlini, Angela Huttner, Peter G Kremsner, Donata Medaglini, Thomas P Monath, Francis M Ndungu, Patricia Njuguna, Tom H M Ottenhoff, David Pejoski, Mark Page, Gianni Pozzi, Francesco Santoro, Claire-Anne Siegrist, Sheri Dubey, Michael Eichberg, Essone P Ndong, Kabwende Lumeka, Helder I Nakaya, Patricia Gonzales Dias Carvalho, Sylvia Rothenberger, Eleonora Vianello, Sravya S Nakka, Suzanne van Veen
Publikováno v:
The Lancet Microbe, Vol 3, Iss 2, Pp e113-e123 (2022)
Summary: Background: A recombinant vesicular stomatitis virus vector expressing the Zaire Ebola virus glycoprotein (rVSVΔG-ZEBOV-GP) vaccine has been reported as safe, immunogenic, and highly protective in a ring vaccination trial. We aimed to ident
Externí odkaz:
https://doaj.org/article/9d0108ac7efd4b3a99b85d9af9182e4b
Autor:
Thomas P Monath, Richard Nichols, Lynda Tussey, Kelly Scappaticci, Thaddeus G Pullano, Mary D Whiteman, Nikos Vasilakis, Shannan L Rossi, Rafael Kroon Campos, Sasha R Azar, Heidi M Spratt, Brent L Seaton, W Tad Archambault, Yanina V Costecalde, Evan H Moore, Roger J Hawks, Joan Fusco
Publikováno v:
PLoS Pathogens, Vol 18, Iss 6, p e1010658 (2022)
Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vacci
Externí odkaz:
https://doaj.org/article/b44f27f75bdd41dfae84c1e5b2c5d0d7
Autor:
Andreza Parreiras Gonçalves, Letícia Trindade Almeida, Izabela Maurício de Rezende, Jordana Rodrigues Barbosa Fradico, Leonardo Soares Pereira, Dario Brock Ramalho, Marcelo Antônio Pascoal Xavier, Carlos Eduardo Calzavara Silva, Thomas P. Monath, Angelle Desiree LaBeaud, Betania Paiva Drumond, Ana Carolina Campi-Azevedo, Olindo Assis Martins-Filho, Andréa Teixeira-Carvalho, Pedro Augusto Alves
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 5 (2024)
ABSTRACTBetween 2016 and 2018, Brazil experienced major sylvatic yellow fever (YF) outbreaks that caused hundreds of casualties, with Minas Gerais (MG) being the most affected state. These outbreaks provided a unique opportunity to assess the immune
Externí odkaz:
https://doaj.org/article/74460047409c4896a13dac51f230339f
Autor:
Thomas P. Monath, Richard Nichols, Friederike Feldmann, Amanda Griffin, Elaine Haddock, Julie Callison, Kimberly Meade-White, Atsushi Okumura, Jamie Lovaglio, Patrick W. Hanley, Chad S. Clancy, Carl Shaia, Wasima Rida, Joan Fusco
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune correlates of protection afforded by PHV02, a recombinant vesicular stomatitis (rVSV) vector vaccine against Nipah virus (NiV) disease, were investigated in the African green monkey (AGM) model. Neutralizing antibody to NiV has bee
Externí odkaz:
https://doaj.org/article/040301b818554706ad4fda037c526189
Autor:
Thomas P. Monath
Publikováno v:
Viruses, Vol 16, Iss 1, p 54 (2023)
Japanese encephalitis virus is a mosquito-borne member of the Flaviviridae family. JEV is the leading cause of viral encephalitis in Asia and is characterized by encephalitis, high lethality, and neurological sequelae in survivors. The virus also cau
Externí odkaz:
https://doaj.org/article/fe8a6ab2db2e4204b217ca64e05c262b
Autor:
John N. Galgiani, Lisa F. Shubitz, Marc J. Orbach, M. Alejandra Mandel, Daniel A. Powell, Bruce S. Klein, Edward J. Robb, Mana Ohkura, Devin J. Seka, Thomas M. Tomasiak, Thomas P. Monath
Publikováno v:
Journal of Fungi, Vol 8, Iss 8, p 838 (2022)
Coccidioidomycosis is an endemic fungal infection that is reported in up to 20,000 persons per year and has an economic impact close to $1.5 billion. Natural infection virtually always confers protection from future exposure, and this suggests that a
Externí odkaz:
https://doaj.org/article/3ddd8dab5dcf4a8ebd3af2a0e07f0366
Autor:
Shixia Wang, Chang Yi Wang, Hui-Kai Kuo, Wen-Jiun Peng, Juin-Hua Huang, Be-Shen Kuo, Feng Lin, Yaw-Jen Liu, Zhi Liu, Huang-Ting Wu, Shuang Ding, Kou-Liang Hou, Jennifer Cheng, Ya-Ting Yang, Ming-Han Jiang, Min-Sheng Wang, Tony Chen, Wei Guo Xia, Ed Lin, Chung Ho Hung, Hui-Jung Chen, Zhonghao Shih, Yi Ling Lin, Valorie Ryan, Mei Mei Hu, D. Gray Heppner, Delphine C. Malherbe, Sivakumar Periasamy, Natalia Kuzmina, Chandru Subramani, Michael Hellerstein, Thomas P. Monath, Alexander Rumyantsev, Alexander Bukreyev, Farshad Guirakhoo
Publikováno v:
Emerging Microbes & Infections. 11:2724-2734
The development of safe and effective vaccines to respond to COVID-19 pandemic/endemic remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine candidate (UB-612) composed of: (i) receptor binding domain of SARS-CoV-2 spike p
Autor:
Thomas P. Monath, Jeroen Kortekaas, Douglas M. Watts, Rebecca C. Christofferson, Angelle Desiree LaBeaud, Brian B Gowen, Clarence J. Peters, Darci R. Smith, Robert Swanepoel, John C. Morrill, Thomas G. Ksiazek, Phillip R Pittman, Stuart T. Nichol, Brian H. Bird, George Bettinger
Publikováno v:
Vaccine: X, Vol 5, Iss , Pp 100060- (2020)
In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome,
Externí odkaz:
https://doaj.org/article/6a96707fc89c478cae04f66418c16927
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 4, Pp 994-1002 (2018)
V920, rVSVΔG-ZEBOV-GP, is a recombinant vesicular stomatitis-Zaire ebolavirus vaccine which has shown an acceptable safety profile and provides a protective immune response against Ebola virus disease (EVD) induced by Zaire ebolavirus in humans. The
Externí odkaz:
https://doaj.org/article/8c092322f70f44c58bb547aba5407f25
Autor:
Thomas P. Monath, Patricia E. Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, Richard Nichols, D. Gray Heppner, Jakub K. Simon, Sheri Dubey, Sean P. Troth, Jayanthi Wolf, Vidisha Singh, Beth-Ann Coller, James S. Robertson
Publikováno v:
Vaccine: X, Vol 1, Iss , Pp - (2019)
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant
Externí odkaz:
https://doaj.org/article/b07b8cb0eee148b0870ad44a4db1f958